{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:46:10Z","timestamp":1792320370638,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-02969-3","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T07:01:46Z","timestamp":1716620506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature"],"prefix":"10.1007","volume":"316","author":[{"given":"Carlos E.","family":"Salazar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir K.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osaigbokan","family":"Aihie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod E.","family":"Nambudiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"key":"2969_CR1","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art. Mol Metab. 46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102. (Epub 2020 Oct 14. PMID: 33068776; PMCID: PMC8085572)","journal-title":"Mol Metab."},{"issue":"12","key":"2969_CR2","doi-asserted-by":"publisher","first-page":"204201882199732","DOI":"10.1177\/2042018821997320","volume":"9","author":"JM Trujillo","year":"2021","unstructured":"Trujillo JM, Nuffer W, Smith BA (2021) GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab 9(12):2042018821997320. https:\/\/doi.org\/10.1177\/2042018821997320. (PMID: 33767808; PMCID: PMC7953228)","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"5","key":"2969_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/14779072.2019.1615444","volume":"17","author":"S Madsbad","year":"2019","unstructured":"Madsbad S (2019) Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients. Expert Rev Cardiovasc Ther 17(5):377\u2013387. https:\/\/doi.org\/10.1080\/14779072.2019.1615444. (Epub 2019 May 17. PMID: 31055989)","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"15","key":"2969_CR4","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1042\/CS20171299","volume":"132","author":"JG Boyle","year":"2018","unstructured":"Boyle JG, Livingstone R, Petrie JR (2018) Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review. Clin Sci (Lond) 132(15):1699\u20131709. https:\/\/doi.org\/10.1042\/CS20171299. (PMID: 30115742)","journal-title":"Clin Sci (Lond)"},{"issue":"Suppl 1","key":"2969_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/jcpt.13225","volume":"45","author":"J Trujillo","year":"2020","unstructured":"Trujillo J (2020) Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther 45(Suppl 1):43\u201360. https:\/\/doi.org\/10.1111\/jcpt.13225. (PMID: 32910487; PMCID: PMC7540535)","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"2969_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","volume":"141","author":"M Elashoff","year":"2011","unstructured":"Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141(1):150\u2013156. https:\/\/doi.org\/10.1053\/j.gastro.2011.02.018. (Epub 2011 Feb 18. PMID: 21334333; PMCID: PMC4404515)","journal-title":"Gastroenterology"},{"issue":"5","key":"2969_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F, Yang N, Huang J, Li Y, Xu L, Li W, Zhang H (2022) Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 182(5):513\u2013519. https:\/\/doi.org\/10.1001\/jamainternmed.2022.0338. (PMID: 35344001; PMCID: PMC8961394)","journal-title":"JAMA Intern Med"},{"key":"2969_CR8","unstructured":"GLP-1 receptor agonist market size report, 2020\u20132027. GLP-1 Receptor agonist market Size report, 2020\u20132027. https:\/\/www.grandviewresearch.com\/industry-analysis\/glp-1-receptor-agonist-market. Accessed 2 Sep 2023"},{"issue":"9","key":"2969_CR9","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.2337\/dc19-0720","volume":"42","author":"O Shamriz","year":"2019","unstructured":"Shamriz O, NaserEddin A, Mosenzon O, Sviri S, Tal Y (2019) Allergic reaction to exenatide and lixisenatide but not to liraglutide: unveiling anaphylaxis to glucagon-like peptide 1 receptor agonists. Diabetes Care 42(9):e141\u2013e142. https:\/\/doi.org\/10.2337\/dc19-0720. (Epub 2019 Jul 11 PMID: 31296642)","journal-title":"Diabetes Care"},{"issue":"5","key":"2969_CR10","doi-asserted-by":"publisher","first-page":"332","DOI":"10.18176\/jiaci.0274","volume":"28","author":"C Ornelas","year":"2018","unstructured":"Ornelas C, Caiado J, Lopes A, Pereira Dos Santos MC, Pereira-Barbosa M (2018) Anaphylaxis to long-acting release exenatide. J Investig Allergol Clin Immunol 28(5):332\u2013334. https:\/\/doi.org\/10.18176\/jiaci.0274. (PMID: 30350785)","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"5","key":"2969_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/8755122514539462","volume":"30","author":"EH Steveling","year":"2014","unstructured":"Steveling EH, Winzeler B, Bircher AJ (2014) Systemic allergic reaction to the GLP-1 receptor agonist exenatide. J Pharm Technol 30(5):182\u2013186. https:\/\/doi.org\/10.1177\/8755122514539462. (Epub 2014 Jun 19. PMID: 34860904; PMCID: PMC5990155)","journal-title":"J Pharm Technol"},{"issue":"6","key":"2969_CR12","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jaip.2014.05.011","volume":"2","author":"E P\u00e9rez","year":"2014","unstructured":"P\u00e9rez E, Mart\u00ednez-Tadeo J, Callero A, Hern\u00e1ndez G, Rodr\u00edguez-Plata E, Garc\u00eda-Robaina JC (2014) A case report of allergy to exenatide. J Allergy Clin Immunol Pract 2(6):822\u2013823. https:\/\/doi.org\/10.1016\/j.jaip.2014.05.011. (Epub 2014 Jul 25 PMID: 25439386)","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"2969_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13223-023-00761-y","volume":"19","author":"OO Ye\u011fit","year":"2023","unstructured":"Ye\u011fit OO, Sar\u0131beyliler G, Karada\u011f P, Demir S, G\u00fcl N, \u00dcnal D, Gelincik AA (2023) The first successful desensitization protocol in exenatide allergy: a case report. Allergy Asthma Clin Immunol 19(1):2. https:\/\/doi.org\/10.1186\/s13223-023-00761-y. (PMID: 36639791; PMCID: PMC9838064)","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"2","key":"2969_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4103\/jdds.jdds_5_19","volume":"23","author":"NF Neel","year":"2019","unstructured":"Neel NF, Ghobara Y, Turkmani M (2019) Liraglutide-induced injection site reaction. J Dermatol Dermatol Surg 23(2):97\u201398. https:\/\/doi.org\/10.4103\/jdds.jdds_5_19","journal-title":"J Dermatol Dermatol Surg"},{"issue":"5","key":"2969_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.18176\/jiaci.0521","volume":"30","author":"A Carvallo","year":"2020","unstructured":"Carvallo A, Silva C, Gastaminza G, D\u2019Amelio CM (2020) Delayed hypersensitivity reaction to liraglutide: a case report. J Investig Allergol Clin Immunol 30(5):367\u2013369. https:\/\/doi.org\/10.18176\/jiaci.0521. (Epub 2020 Apr 17 PMID: 32301438)","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"SUPPL 110","key":"2969_CR16","first-page":"52","volume":"76","author":"J Penella","year":"2021","unstructured":"Penella J, Gomez M, Gil J, Ross A, Quilez E, Mendoza A (2021) Semaglutide as alternative to liraglutide immediate hypersensitivity: a case report. Allergy Eur J Allergy Clin Immunol. 76(SUPPL 110):52","journal-title":"Allergy Eur J Allergy Clin Immunol."},{"issue":"4","key":"2969_CR17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.36849\/JDD.6550","volume":"22","author":"S Ouellette","year":"2023","unstructured":"Ouellette S, Frias G, Shah R, Alamgir M, Wassef C (2023) Dermal hypersensitivity reaction to semaglutide: two case reports. J Drugs Dermatol 22(4):413\u2013416. https:\/\/doi.org\/10.36849\/JDD.6550. (PMID: 37026881)","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"2969_CR18","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.4158\/ACCR-2018-0418","volume":"5","author":"A Ito","year":"2019","unstructured":"Ito A, Kamata A, Nozaki A, Ando T, Kawakami A (2019) Hypothyroidism could be a potential factor to prolong subcutaneous nodules of exenatide once weekly: a case report. AACE Clin Case Rep 5(3):e197\u2013e200. https:\/\/doi.org\/10.4158\/ACCR-2018-0418. (PMID: 31967033; PMCID: PMC6876937)","journal-title":"AACE Clin Case Rep"},{"issue":"Suppl 1","key":"2969_CR19","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1093\/ajcp\/aqaa161.058","volume":"154","author":"G Williams","year":"2020","unstructured":"Williams G, Kwan E, Giraldo CN, Lincoln M, Lewin-Smith M (2020) Panniculitis at the site of injection: infection or foreign body reaction? Am J Clin Pathol 154(Suppl 1):S29. https:\/\/doi.org\/10.1093\/ajcp\/aqaa161.058","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"2969_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/cup.12246","volume":"41","author":"NC Boysen","year":"2014","unstructured":"Boysen NC, Stone MS (2014) Eosinophil-rich granulomatous panniculitis caused by exenatide injection. J Cutan Pathol 41(1):63\u201365. https:\/\/doi.org\/10.1111\/cup.12246. (Epub 2013 Nov 14 PMID: 24224897)","journal-title":"J Cutan Pathol"},{"issue":"10","key":"2969_CR21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1097\/DAD.0000000000000243","volume":"37","author":"I Andr\u00e9s-Ramos","year":"2015","unstructured":"Andr\u00e9s-Ramos I, Blanco-Barrios S, Fern\u00e1ndez-L\u00f3pez E, Santos-Briz \u00c1 (2015) Exenatide-induced eosinophil-rich granulomatous panniculitis: a novel case showing injected microspheres. Am J Dermatopathol 37(10):801\u2013802. https:\/\/doi.org\/10.1097\/DAD.0000000000000243. (PMID: 25545186)","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"2969_CR22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.5021\/ad.2020.32.3.230","volume":"32","author":"JW Ko","year":"2020","unstructured":"Ko JW, Park KD, Lee Y, Lee JH, Hong DK (2020) Eosinophilic panniculitis following the subcutaneous injection of exenatide extended-release. Ann Dermatol 32(3):230\u2013232. https:\/\/doi.org\/10.5021\/ad.2020.32.3.230. (Epub 2020 Apr 24. PMID: 33911742; PMCID: PMC7992610)","journal-title":"Ann Dermatol"},{"issue":"5","key":"2969_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/cup.14193","volume":"49","author":"CS Zhu","year":"2022","unstructured":"Zhu CS, Kwan EA, Williams GM, Lewin-Smith M, Lincoln MS, Lee AJ (2022) Exenatide-induced granulomatous panniculitis associated with poly(d, l-lactide-co-glycolide). J Cutan Pathol 49(5):496\u2013499. https:\/\/doi.org\/10.1111\/cup.14193","journal-title":"J Cutan Pathol"},{"issue":"11","key":"2969_CR24","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/DAD.0000000000000952","volume":"40","author":"CI Vidal","year":"2018","unstructured":"Vidal CI, Chaudhry S, Burkemper NM (2018) Exenatide-induced panniculitis: utility of the acid-fast stain to identify injected microspheres. Am J Dermatopathol 40(11):867\u2013869. https:\/\/doi.org\/10.1097\/DAD.0000000000000952. (PMID: 28700374)","journal-title":"Am J Dermatopathol"},{"key":"2969_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.295","author":"EA Kwan","year":"2021","unstructured":"Kwan EA, Williams GM, Lewin-Smith MR, Lincoln MS, Lee AJ (2021) 25734 Migratory panniculitis of the pannus. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.295","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2969_CR26","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/DAD.0000000000000036","volume":"36","author":"SJ Shan","year":"2014","unstructured":"Shan SJ, Guo Y (2014) Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site. Am J Dermatopathol 36(6):510\u2013512. https:\/\/doi.org\/10.1097\/DAD.0000000000000036. (PMID: 24366197)","journal-title":"Am J Dermatopathol"},{"issue":"8","key":"2969_CR27","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.jdcr.2018.06.009.PMID:30238049;PMCID:PMC6143713","volume":"4","author":"K Riswold","year":"2018","unstructured":"Riswold K, Flynn V (2018) Persistent injection site nodules from exenatide: successful treatment with intralesional triamcinolone. JAAD Case Rep 4(8):830\u2013832. https:\/\/doi.org\/10.1016\/j.jdcr.2018.06.009.PMID:30238049;PMCID:PMC6143713","journal-title":"JAAD Case Rep"},{"issue":"12","key":"2969_CR28","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/ggi.13799","volume":"19","author":"G Fukuda","year":"2019","unstructured":"Fukuda G, Yoshida T, Hirayama A, Umezawa Y, Takemoto M (2019) Dulaglutide-related bullous pemphigoid in a patient with type 2 diabetes: a case report. Geriatr Gerontol Int 19(12):1289\u20131290. https:\/\/doi.org\/10.1111\/ggi.13799. (PMID: 31823494)","journal-title":"Geriatr Gerontol Int"},{"issue":"5","key":"2969_CR29","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.12788\/cutis.0262","volume":"107","author":"MK Collins","year":"2021","unstructured":"Collins MK, Choudhary S, Ho J, Bunimovich YL (2021) Bullous pemphigoid triggered by liraglutide. Cutis 107(5):E9\u2013E11. https:\/\/doi.org\/10.12788\/cutis.0262. (PMID: 34288861)","journal-title":"Cutis"},{"issue":"15","key":"2969_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jdcr.2021.07.027","volume":"5","author":"CP Burruss","year":"2021","unstructured":"Burruss CP, Jones JM, Burruss JB (2021) Semaglutide-associated bullous pemphigoid. JAAD Case Rep 5(15):107\u2013109. https:\/\/doi.org\/10.1016\/j.jdcr.2021.07.027. (PMID: 34466645; PMCID: PMC8385392)","journal-title":"JAAD Case Rep"},{"issue":"1","key":"2969_CR31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21536","volume":"14","author":"G Kyriakos","year":"2022","unstructured":"Kyriakos G, Diamantis E, Memi E, Elefsiniotis I (2022) An uncommon case of dulaglutide-related morbilliform drug eruption. Cureus 14(1):e21536. https:\/\/doi.org\/10.7759\/cureus.21536. (PMID: 35223310; PMCID: PMC8864188)","journal-title":"Cureus"},{"issue":"4","key":"2969_CR32","first-page":"13","volume":"13","author":"PV Rzepka","year":"2020","unstructured":"Rzepka PV, Kaffenberger JA (2020) a case of morbilliform drug eruption to dulaglutide. J Clin Aesthet Dermatol. 13(4):13 (Epub 2020 Apr 1. PMID: 33144906; PMCID: PMC7605389)","journal-title":"J Clin Aesthet Dermatol."},{"issue":"11","key":"2969_CR33","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20041.PMID:34987924;PMCID:PMC8717822","volume":"13","author":"N Karakousis","year":"2021","unstructured":"Karakousis N, Kostakopoulos NA, Georgakopoulou VE, Pyrgioti EE, Georgakopoulos PN (2021) A rare case of dulaglutide-associated angioedema in a male patient. Cureus 13(11):e20041. https:\/\/doi.org\/10.7759\/cureus.20041.PMID:34987924;PMCID:PMC8717822","journal-title":"Cureus"},{"issue":"1","key":"2969_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-235663.PMID:33461993;PMCID:PMC7813304","volume":"14","author":"F Mahfooz","year":"2021","unstructured":"Mahfooz F, Aylor K, Mathew J Jr, Reichmuth M (2021) Extending our understanding of exenatide: a rare case of angio-oedema. BMJ Case Rep 14(1):e235663. https:\/\/doi.org\/10.1136\/bcr-2020-235663.PMID:33461993;PMCID:PMC7813304","journal-title":"BMJ Case Rep"},{"issue":"10","key":"2969_CR35","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/ijd.14272","volume":"58","author":"CR Hamann","year":"2019","unstructured":"Hamann CR, Chung C, Kaffenberger BH (2019) Pyoderma gangrenosum associated with dulaglutide therapy. Int J Dermatol 58(10):1202\u20131204. https:\/\/doi.org\/10.1111\/ijd.14272. (Epub 2018 Oct 21 PMID: 30345551)","journal-title":"Int J Dermatol"},{"issue":"5","key":"2969_CR36","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jdiacomp.2012.05.018","volume":"26","author":"F Besemer","year":"2012","unstructured":"Besemer F, Verschoor AJ, Diamant M, Hoogma RP (2012) Vesiculopustular dermatosis: an uncommon side-effect of liraglutide? J Diabetes Complicat 26(5):458\u2013459. https:\/\/doi.org\/10.1016\/j.jdiacomp.2012.05.018. (Epub 2012 Jun 23 PMID: 22727533)","journal-title":"J Diabetes Complicat"},{"issue":"3","key":"2969_CR37","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1111\/ijd.15863","volume":"61","author":"E Bostan","year":"2022","unstructured":"Bostan E, Akdogan N, Gokoz O (2022) Paradoxical new-onset psoriasiform dermatitis associated with exenatide administration. Int J Dermatol 61(3):e112\u2013e114. https:\/\/doi.org\/10.1111\/ijd.15863. (Epub 2021 Aug 17 PMID: 34403495)","journal-title":"Int J Dermatol"},{"issue":"3","key":"2969_CR38","doi-asserted-by":"publisher","first-page":"E78","DOI":"10.1002\/ajh.25381","volume":"94","author":"Y Vallatharasu","year":"2019","unstructured":"Vallatharasu Y, Hayashi-Tanner Y, Polewski PJ, Bottner WA, Rosenstein LJ, Uprety D, Bista A, Farnen JP, Aster R (2019) Severe, prolonged thrombocytopenia in a patient sensitive to exenatide. Am J Hematol 94(3):E78\u2013E80. https:\/\/doi.org\/10.1002\/ajh.25381. (Epub 2018 Dec 28. PMID: 30575104; PMCID: PMC7942234)","journal-title":"Am J Hematol"},{"issue":"10","key":"2969_CR39","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1001\/jamadermatol.2019.1893","volume":"155","author":"AL Cogen","year":"2019","unstructured":"Cogen AL, Desai K, Elder D, Rosenbach M (2019) Acute photodistributed exanthematous pustulosis associated with liraglutide treatment. JAMA Dermatol 155(10):1198\u20131200. https:\/\/doi.org\/10.1001\/jamadermatol.2019.1893. (PMID: 31389984)","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2969_CR40","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/all.12350","volume":"69","author":"P Demoly","year":"2014","unstructured":"Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, Khan DA, Lang DM, Park HS, Pichler W, Sanchez-Borges M, Shiohara T, Thong BY (2014) International consensus on drug allergy. Allergy 69(4):420\u2013437. https:\/\/doi.org\/10.1111\/all.12350. (PMID: 24697291)","journal-title":"Allergy"},{"issue":"11","key":"2969_CR41","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","volume":"27","author":"JB Buse","year":"2004","unstructured":"Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, Exenatide-113 Clinical Study Group (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27(11):2628\u20132635. https:\/\/doi.org\/10.2337\/diacare.27.11.2628. (PMID: 15504997)","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"2969_CR42","first-page":"S341","volume":"53","author":"J Buse","year":"2010","unstructured":"Buse J, Montanya E, Sesti G et al (2010) The incidence of antibody formation and the levels of antibodies are lower with liraglutide than exenatide in a head-to-head comparison. Diabetologia 53(suppl 1):S341","journal-title":"Diabetologia"},{"issue":"2 Pt 1","key":"2969_CR43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/s0190-9622(96)80117-4","volume":"34","author":"J Adame","year":"1996","unstructured":"Adame J, Cohen PR (1996) Eosinophilic panniculitis: diagnostic considerations and evaluation. J Am Acad Dermatol 34(2 Pt 1):229\u2013234. https:\/\/doi.org\/10.1016\/s0190-9622(96)80117-4. (PMID: 8642087)","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"2969_CR44","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1089\/dia.2011.0050","volume":"13","author":"MB DeYoung","year":"2011","unstructured":"DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P (2011) Encapsulation of exenatide in poly-(d, l-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 13(11):1145\u20131154. https:\/\/doi.org\/10.1089\/dia.2011.0050","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"2969_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3810\/pgm.2013.05.2660","volume":"125","author":"M Grimm","year":"2013","unstructured":"Grimm M, Han J, Weaver C, Griffin P, Schulteis CT, Dong H, Malloy J (2013) Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials. Postgrad Med 125(3):47\u201357. https:\/\/doi.org\/10.3810\/pgm.2013.05.2660. (PMID: 23748506)","journal-title":"Postgrad Med"},{"issue":"2","key":"2969_CR46","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","volume":"94","author":"D Miyamoto","year":"2019","unstructured":"Miyamoto D, Santi CG, Aoki V, Maruta CW (2019) Bullous pemphigoid. An Bras Dermatol 94(2):133\u2013146. https:\/\/doi.org\/10.1590\/abd1806-4841.20199007. (Epub 2019 May 9. PMID: 31090818; PMCID: PMC6486083)","journal-title":"An Bras Dermatol"},{"issue":"1","key":"2969_CR47","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/2013.jamadermatol.376","volume":"149","author":"A Lloyd-Lavery","year":"2013","unstructured":"Lloyd-Lavery A, Chi CC, Wojnarowska F, Taghipour K (2013) The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol 149(1):58\u201362. https:\/\/doi.org\/10.1001\/2013.jamadermatol.376. (PMID: 23324757)","journal-title":"JAMA Dermatol"},{"issue":"6","key":"2969_CR48","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","volume":"78","author":"M Benzaquen","year":"2018","unstructured":"Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard MA, Feldmeyer L (2018) Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol 78(6):1090\u20131096. https:\/\/doi.org\/10.1016\/j.jaad.2017.12.038. (Epub 2017 Dec 21 PMID: 29274348)","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"2969_CR49","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1016\/j.jid.2021.05.015","volume":"141","author":"O Varpuluoma","year":"2021","unstructured":"Varpuluoma O, Jokelainen J, Huilaja L, Tasanen K (2021) GLP-1 analogs and SGLT2 inhibitors do not increase risk of bullous pemphigoid. J Invest Dermatol 141(12):2969-2972.e1. https:\/\/doi.org\/10.1016\/j.jid.2021.05.015. (Epub 2021 Jun 8 PMID: 34116060)","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2969_CR50","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.tox.2004.12.023","volume":"209","author":"N Yawalkar","year":"2005","unstructured":"Yawalkar N (2005) Drug-induced exanthems. Toxicology 209(2):131\u2013134. https:\/\/doi.org\/10.1016\/j.tox.2004.12.023. (PMID: 15767025)","journal-title":"Toxicology"},{"issue":"1","key":"2969_CR51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40257-017-0308-7","volume":"19","author":"JY Wang","year":"2018","unstructured":"Wang JY, French LE, Shear NH, Amiri A, Alavi A (2018) Drug-induced pyoderma gangrenosum: a review. Am J Clin Dermatol 19(1):67\u201377. https:\/\/doi.org\/10.1007\/s40257-017-0308-7. (PMID: 28624960)","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2969_CR52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/2042018814543483","volume":"5","author":"MR Al-Badri","year":"2014","unstructured":"Al-Badri MR, Azar ST (2014) Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis. Ther Adv Endocrinol Metab 5(2):34\u201338. https:\/\/doi.org\/10.1177\/2042018814543483. (PMID: 25152810; PMCID: PMC4141528)","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"6","key":"2969_CR53","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1538-7836.2009.03360.x","volume":"7","author":"RH Aster","year":"2009","unstructured":"Aster RH, Curtis BR, McFarland JG, Bougie DW (2009) Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost 7(6):911\u2013918. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03360.x. (Epub 2009 Apr 2. PMID: 19344362; PMCID: PMC2935185)","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2969_CR54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.tmrv.2013.05.005","volume":"27","author":"DM Arnold","year":"2013","unstructured":"Arnold DM, Nazi I, Warkentin TE, Smith JW, Toltl LJ, George JN, Kelton JG (2013) Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev 27(3):137\u2013145. https:\/\/doi.org\/10.1016\/j.tmrv.2013.05.005. (Epub 2013 Jul 8. PMID: 23845922; PMCID: PMC3728035)","journal-title":"Transfus Med Rev"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02969-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-02969-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02969-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T11:33:43Z","timestamp":1719401623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-02969-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":54,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["2969"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-02969-3","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"13 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB approval status"}}],"article-number":"248"}}